Vaccines: Valneva announces positive Phase 1 interim results for Chikungunya vaccine candidate
by Press Release from Outbreak News Today on (#46FYZ)
Just weeks after announcing the U.S. Food and Drug Administration (FDA) granted Fast Track designation for VLA1553, their Chikungunya vaccine candidate, Valneva announced today positive Phase 1 interim results for the vaccine. The primary objective of VLA1553-101 Phase 1 study was to assess the overall safety and immunogenicity profile 28 days after a single vaccination across three dose levels. ["]
The post Vaccines: Valneva announces positive Phase 1 interim results for Chikungunya vaccine candidate appeared first on Outbreak News Today.